We and others have also reported that the chemotherapeutic agent gemcitabine induces NF-κB activity in pancreatic cancer cells in vitro, suggesting that NF-κB activation may play a role in chemoresistance to gemcitabine [9,17-20]. The gene discussed is NFKB1; the disease is pancreatic neoplasm.